Osteoarthritis (OA) is the most common form of arthritis and it is often associated with significant disability and impaired quality of life. Once thought to be caused by an age-related 'wearing out' of articular cartilage, it is now recognized to be a dynamic process in which cartilage degradation alternates with repair. Several expert guidelines for the management of OA exist, which concur in their recommendations for a stepwise approach to the employment of pharmacological agents and the introduction of suggestions to extend the use of agents such as topical nonsteroidal anti-inflammatory drugs, especially for mild-to-moderate forms of the disease. They also emphasize the importance of non-pharmacological measures, such as nutraceuticals, education, diet, exercise and the use of aids in improving signs and symptoms and slowing progression. In many countries, effective medicinal and nutraceutical agents are available 'overthe-counter'. This review explains the modern approach to the management of mild-to-moderate osteoarthritic pain.
Introduction
Few diseases have seen more dramatic changes in perception than osteoarthritis (OA). It has always been seen as a milder disease than rheumatoid arthritis (RA) and, 50 years ago, was thought to be an inevitable part of the ageing process caused by the natural wearing-out of cartilage.
Research has begun to shed some light on the true nature of the disease process. This research has indicated that the structure primarily affected by OA appears to be cartilage, which in young and healthy people has an amazing capacity for repair, but it can lose this property with age. 1 It is also known that there is a very important genetic basis and that injury can exacerbate the problem; an old fashioned open meniscectomy, for example, can increase the risk of disease in the knee. 2 It is recognized that, in many cases, both of these factors are at work; for example, a patient with a hereditary predisposition having particularly severe problems at the site of a mechanical stress, such as in the big toe of a patient with pronated ankles. Also, it is increasingly clear that inflammation is an important part of the process, with the
EC Huskisson A holistic approach to pain management in osteoarthritis
cardinal signs of warm joints and morning stiffness being evident. 3 Synovial inflammation is apparent at histology and is thought to be secondary to changes in cartilage. 3 Much can be done to relieve the symptoms and perhaps even improve the prognosis of OA; the days of believing it to be an inevitable part of the ageing process are gone. This review aims to assess the available options for the management of mild-to-moderate pain due to OA and to provide guidance about the means available to manage OA symptoms in a holistic way.
Prevalence and symptoms of OA
Osteoarthritis is very common and the signs and symptoms are variable ( Table 1) . The disease becomes symptomatic in around 15% of all adults > 40 years of age and its impact can be debilitating, especially when the knee is affected. 4 OA is about 10 times more common than RA. 5 Most physicians are going to be asked to deal with it during their career and it is a particularly common problem in general practice, accounting for 30% of physician visits. 3 The incidence of OA is expected to double between the years 2000 and 2020, becoming an increasingly serious burden to healthcare systems. 6 Most patients will, however, never see a rheumatologist or an orthopaedic surgeon and many will never consult a physician about their joints, relying on over-the-counter (OTC) remedies and advice from friends, family, pharmacists and the media. The most common joint affected by OA is the knee, with a prevalence of 18.1% in the UK. 7 Symptomatic OA of the hand has a prevalence of about 2.5% and hip OA is estimated to affect 0.7 -4.4% of patients. 8 OA evolves at different rates: knee OA develops slowly, often remaining relatively stable for many years, while hand OA is usually complete after a relapsing and remitting course spanning several years. 8 Pain is the major symptom but affected joints also become stiff, particularly after inactivity, and there may be functional problems such as difficulty in walking. 3 OA is as often bilateral and symmetrical as RA, but fewer joints are affected. Typically, OA is found at one, two, three or four sites. Common sites, apart from the knees, are the hands, feet, hips, spine and ankles. The site affected and the severity of pain will influence the choice of treatment. 3 
Guidelines for OA management
Several sets of guidelines for the management of OA in general, and of the hip and knee in particular, have been proposed. 9 -11 Those produced by the Osteoarthritis Research Society International (OARSI) 10 and the European League Against Rheumatism (EULAR) 9, 12 have been developed using a clinical evidence-based plus expert opinion approach and they comprise 25 and 10 recommendations, respectively (Tables 2 and 3 ).
All guidelines recommend starting with the simplest and safest treatments and moving up the ladder if necessary, the sort of advice that has always been put forward in 10 15 Topical NSAIDs and capsaicin can be effective as adjunctives and alternatives to oral analgesic/anti-inflammatory agents in knee OA.
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16 Intra-articular (IA) injections with corticosteroids can be used in the treatment of hip or knee OA, and should be considered particularly when patients have moderate-to-severe pain not responding satisfactorily to oral analgesic/anti-inflammatory agents and in patients with symptomatic knee OA with effusions or other physical signs of local inflammation.
17 Injections of IA hyaluronate may be useful in patients with knee or hip OA. They are characterized by delayed onset, but prolonged duration, of symptomatic benefit when compared to IA injections of corticosteroids.
18 Treatment with glucosamine and/or chondroitin sulphate may provide symptomatic benefit in patients with knee OA. If no response is apparent within 6 months treatment should be discontinued.
19 In patients with symptomatic knee OA glucosamine sulphate and chondroitin sulphate may have structure-modifying effects while diacerein may have structure-modifying effects in patients with symptomatic OA of the hip. 20 The use of weak opioids and narcotic analgesics can be considered for the treatment of refractory pain in patients with hip or knee OA, where other pharmacological agents have been ineffective, or are contraindicated. Stronger opioids should only be used for the management of severe pain in exceptional circumstances. Non-pharmacological therapies should be continued in such patients and surgical treatments should be considered. 21 Patients with hip or knee OA who are not obtaining adequate pain relief and functional improvement from a combination of nonpharmacological and pharmacological treatment should be considered for joint replacement surgery. Replacement arthroplasties are effective, and cost-effective interventions for patients with significant symptoms, and/or functional limitations associated with a reduced health-related quality of life, despite conservative therapy.
22 Unicompartmental knee replacement is effective in patients with knee OA restricted to a single compartment. 23 Osteotomy and joint preserving surgical procedures should be considered in young adults with symptomatic hip OA, especially in the presence of dysplasia. For the young and physically active patient with significant symptoms from unicompartmental knee OA, high tibial osteotomy may offer an alternative intervention that delays the need for joint replacement some 10 years.
24 The roles of joint lavage and arthroscopic debridement in knee OA are controversial. Although some studies have demonstrated short-term symptom relief, others suggest that improvement in symptoms could be attributable to a placebo effect.
25 In patients with OA of the knee, joint fusion can be considered as a salvage procedure when joint replacement has failed.
Text in bold represents guidelines that are of special relevance to the content of this paper. TENS, Transcutaneous electrical nerve stimulation; NSAIDs, non-steroidal anti-inflammatory drugs; GI, gastrointestinal; COX-2, cyclo-oxygenase 2; PPI, proton pump inhibitor. 9 Intra-articular injection of a long-acting corticosteroid is indicated for flare of knee pain, especially if accompanied by effusion.
10 Joint replacement must be considered in patients who have radiographic evidence of knee OA and who have refractory pain and disability.
Text in bold represents guidelines that are of special relevance to the content of this paper. NSAIDs, non-steroidal anti-inflammatory drugs; COX-2, cyclo-oxygenase 2. A holistic approach to pain management in osteoarthritis the management of RA. This approach in OA management has been reflected in the 2008 guidelines from the National Institute for Health and Clinical Excellence (NICE) in the UK, 11 summarized in Table 4 . These expert guidelines emphasize the importance of following a holistic approach in managing OA: 'Optimal management of OA requires a combination of nonpharmacological and pharmacological modalities'. 9, 10, 12 The range of recommended therapeutic modalities originally listed by Lozada and Altman 13 is shown in Table 5 .
The American College of Rheumatology (ACR) discussed updated recommendations for the management of knee, hip and hand OA during their 2009 meeting and also recommended a combined approach for the management of OA, comprising nonpharmacological and pharmacological modalities; it included, for the first time, topical non-steroidal anti-inflammatory drugs (NSAIDs) as a treatment for patients ≥ 75 years with knee and hand OA. 14 Inclusion of topical NSAIDs in the guidelines indicates that they are recognized by the ACR as effective and, overall, safer than oral NSAIDs since they are recommended as treatment for patients ≥ 75 years who are usually at a higher risk of suffering adverse 
determine the severity of the disease is carried out, taking into account factors such as the severity of joint pain, the amount of anatomical damage, the activity of the disease, inflammation, the extent of joint involvement, and the likely outcome and particular problems that need to be addressed.
The first step in OA management is to inform the patient about the nature and causes of the disease and to give advice about the importance of self-help and patient-driven therapies. There is a high level of evidence from randomized controlled trials (RCTs) for the importance of patient education in improving the clinical outcome. 10 Many patients with OA (particularly when it affects the knees) are overweight, partly because they have become immobile. Weight reduction will help and, in the author's opinion, a Mediterranean diet, rich in fish and vegetables, is particularly suitable. Clinical trials have confirmed the efficacy of weight reduction in treating OA, but suggest that regular supervision and encouragement is required; for example, a significant improvement in pain and an improvement in function was reported by Christensen et al. 15 in such a study. Other studies, however, have shown a poor correlation between weight loss and pain improvement, indicating that diet is probably more important than the weight loss. 16 Physical exercise has also been shown to be useful but, again, supervision seems to be required. Deyle et al. 17 18 -22 The role that these supplements can play in the longterm management of OA is reflected in the EULAR recommendations for the management of knee OA, 9 which includes glucosamine and chondroitin as EC Huskisson A holistic approach to pain management in osteoarthritis 'symptomatic slow-acting drugs for OA which may modify the structure of cartilage.' Similarly, the OARSI guidelines suggest that treatment with glucosamine and/or chondroitin may provide symptomatic benefit and they may have structuremodifying effects. 10 Glucosamine and chondroitin work slowly, taking a few weeks to become effective and should be given for at least 4 weeks before an assessment is made. 18 The evidence for glucosamine, chondroitin and their combination is reviewed below and confirms their efficacy and safety in the treatment of OA.
GLUCOSAMINE
Glucosamine is a monosaccharide, 2-amino-2-deoxy-D-glucose (C 6 H 14 NO 5 ) (Fig. 3) , with a molecular weight of 179.2 Da. It is usually extracted from marine crustacea. It is naturally synthesized in the human body from glucose and is an important precursor in the biosynthesis of glycosylated proteins and lipids. It acts as one of the principal substrates during the synthesis of glycosaminoglycans, proteoglycans and hyaluronic acid, which are structural components of articular cartilage. 18 
CHONDROITIN
Chondroitin is a high molecular weight glycosaminoglycan that is found in cartilage and connective tissue. It is produced from animal sources including bovine trachea and shark cartilage. It consists of an alternating sequence of D-glucuronate and N-acetylgalactosamine-4/6-sulphate residues linked through alternating bonds (Fig. 4 ). It has a molecular weight of 10 000 -50 000 Da. Like glucosamine, it is hydrophilic. It is soluble in water, producing a viscous fluid similar to sodium hyaluronate. Chondroitin sulphate constitutes the majority of the glycosaminoglycans in articular cartilage 23 and, therefore, is essential for the structural and functional integrity of the joints. 24 Chondroitin sulphate has been reported to maintain viscosity in joints, stimulate cartilage repair and inhibit enzymes that degrade cartilage. 25 
PHARMACOKINETICS

Glucosamine
Glucosamine taken orally is 90% absorbed. 26 It then undergoes first-pass metabolism so that only 25% bioavailability is achieved by oral administration compared with 96% with intravenous administration. 26, 27 It can be taken in the form of the sulphate or the hydrochloride. The salts of glucosamine are ionized in the stomach, making glucosamine available for absorption in the small bowel. It is extensively metabolized and the metabolites are excreted predominantly in urine. 26 Plasma levels of glucosamine after oral administration of a single dose of 1500 mg glucosamine sulphate reach a peak of 1200 ng/ml after about 4 h, declining to the 
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baseline level after about 48 h. 28 Plasma concentrations range from 600 to 4061 ng/ml and synovial fluid concentrations range from 577 to 3248 ng/ml. Plasma and synovial fluid levels are highly correlated. 28 Measuring plasma and synovial fluid levels clearly shows that glucosamine is absorbed following oral administration, providing significant increases in levels of glucosamine both in the plasma and synovial fluid.
Chondroitin
Chondroitin is not as well absorbed as glucosamine. 25 Bioavailability has been estimated at 12 -13%. 29 Mean plasma levels over a 30-day period of administration of 800 mg/day were between 1.7 and 1.89 µg/ml. 29
MODES OF ACTION
The original rationale for taking glucosamine and chondroitin was to provide the substrate or building blocks for the biosynthesis of proteoglycan, 30 which is degraded in OA cartilage. It is probably naïve to think that this is the mode of action of these compounds since there is no evidence of a shortage of proteoglycan in patients with OA. 30 It seems more likely that glucosamine and chondroitin promote proteoglycan synthesis by chondrocytes, help maintain viscosity and inhibit the degradative enzymes that lead to the premature breakdown of cartilage in OA. 30 
EFFICACY OF GLUCOSAMINE PLUS CHONDROITIN COMBINATION
Glucosamine and chondroitin are often taken together and it is appropriate to look first at the efficacy of the combination. The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) was a multicentre randomized, double-blind, placebo-and celecoxib-controlled study carried out in 1583 patients with OA. 31 The treatment groups received glucosamine hydrochloride 1500 mg/day, chondroitin sulphate 1200 mg/day, the combination of these two agents, placebo or celecoxib 200 mg/day for 6 months. 31 The groups were stratified by pain according to baseline WOMAC index scores. Mild pain was defined as 125 -300 on the WOMAC pain score and there were 1229 
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study participants (78%) in this category. 31 Moderate-to-severe pain was defined as 301 -400 on the WOMAC pain score and there were 354 study participants (22%) in this category. The primary outcome was at least a 20% reduction in the sum score of the WOMAC pain subscale at 24 weeks. Secondary outcomes were the degree of stiffness and function subscales of the WOMAC index, patient's global assessment of disease status, response to therapy using a visual analogue scale (VAS), the investigator's global assessment of disease status using a VAS, the presence or absence of soft tissue swelling, effusion or both in the index knee, the quality of life improvement, the physical function using a health assessment questionnaire, and the use of paracetamol (acetaminophen). 31 Analysis of the data from the 354 patients with moderate-or-severe pain demonstrated a significant reduction in pain in patients receiving the combination of glucosamine and chondroitin compared with placebo. The combination of glucosamine and chondroitin was the most effective of the treatments investigated. Glucosamine alone and celecoxib were less effective. Chondroitin alone was a little better than placebo. The response rate to the combination of glucosamine and chondroitin using OMERACT (Outcome Measures in Rheumatology)-OARSI criteria was 79.2% compared with 54.3% with placebo (P = 0.002). 31 In the group as a whole and in patients with mild pain, glucosamine, chondroitin and the combination resulted in numerical superiority against placebo, but the differences were not statistically significant. It might have been predicted that this would be the case as a 20% decrease in the pain score was unlikely to be achieved in patients with mild pain, especially since there was a very high placebo response rate of just over 60%, much higher than the 35% that had been predicted. 31 There were 77 reports of serious adverse events during the study. Of these, only three were attributed to study treatments. Most side-effects were mild, such as an upset stomach, and they were spread evenly across the different treatment groups. No change in glucose tolerance was seen for glucosamine nor was an increased incidence of cardiovascular events seen with celecoxib. 31 Leffler et al. 32 undertook a double-blind, crossover trial comparing the combination of glucosamine hydrochloride 1500 mg/day, chondroitin sulphate 1200 mg/day and manganese ascorbate 228 mg/day for 16 weeks in patients with knee OA. Knee OA symptoms were significantly relieved, as demonstrated by the summary disease score (-16.3%), patient assessment of treatment effect, VAS for pain recorded at clinic visits (-26.6%) and in a diary (-28.6%), and physical examination score (-43.3%). 32 Das and Hammad 33 used the combination of glucosamine hydrochloride 2000 mg/day, chondroitin sulphate 1600 mg/day and manganese ascorbate 304 mg/day and found it to be superior to placebo in patients with mild-to-moderate OA of the knee. In total, 52% of patients responded to treatment compared with 28% of those treated with placebo. 33 In contrast to the GAIT study, 31 there was no significant improvement in patients with severe disease. 33 Cohen et al. 34 compared a placebo cream with a spray containing glucosamine sulphate, chondroitin sulphate and shark cartilage and observed significant relief of pain after 4 weeks with the active preparation. They found a significant difference in the reduction of pain scores measured by a VAS in favour of the activetreatment group. After 4 weeks, the EC Huskisson A holistic approach to pain management in osteoarthritis difference was 1.2 cm (P = 0.03) and, after 8 weeks, the mean difference was even greater (1.8 cm; P = 0.002) between the placebo cream and the active-treatment spray. 34 
EFFICACY OF GLUCOSAMINE ALONE
Clinical data have clearly demonstrated the efficacy of glucosamine, as outlined in Table  7 . 20,21,35 -49 Numerous studies with active or placebo controls have demonstrated significant improvement in pain scores and functional scores such as the Lequesne and WOMAC indices in the glucosamine groups compared with controls. 39 -41,43,44,47 Additionally, a number of studies have noted a marked 'carryover' effect with glucosamine treatment with benefits persisting for several weeks after cessation of treatment. 41, 50 A Cochrane review meta-analysis evaluating the efficacy of glucosamine in OA provided some evidence that glucosamine may be effective. 51 The pooled standardized mean difference comparing glucosamine with placebo with regards to pain reduction and function was calculated to be 0.47, which represents a moderate clinically significant benefit in favour of glucosamine. 52 The meta-analysis also determined that glucosamine produced similar symptomatic benefits as NSAIDs and suggested that glucosamine therapy may represent a significant breakthrough in the pharmacological management of OA. 51 Nevertheless, because some RCTs did not show a benefit in favour of glucosamine and there was heterogeneity in study designs (e.g. measurement scales used, patient populations, disease stages), the overall results of the meta-analysis were deemed inconclusive. 51 
COMPARISON OF GLUCOSAMINE AND NSAIDs
A number of studies have compared the efficacy of glucosamine with prescription doses of ibuprofen in OA and these are summarized in Table 8 . 19 -22 In general, glucosamine has been found to be as effective or more effective than ibuprofen but with a slower onset of action.
IMPACT OF GLUCOSAMINE ON THE COURSE OF OA
A series of studies has demonstrated that long-term treatment with glucosamine may help to delay the progression of knee OA. 35, 41, 43, 53, 54 These studies have shown a beneficial effect on the radiological progression of OA, indicating that glucosamine may act as a disease-modifying agent for OA. One of the most important trials was conducted by Reginster et al. 43 The investigators assessed the effects of glucosamine sulphate on the symptoms and long-term progression of OA in a randomized, double-blind, placebocontrolled trial involving 212 patients with knee OA who were randomly assigned to receive either 1500 mg/day of glucosamine or placebo for 3 years. The primary endpoints were changes in radiological signs and the WOMAC index score. Weightbearing periarticular X-rays of the knees were used to measure joint space width in the medial compartment of the knee; joint space was similar at enrolment in the two groups. Patients receiving placebo showed progressive narrowing of the joint space whereas there was no significant joint space loss in the 106 patients receiving glucosamine. After 2 years, there was joint space loss of 0.31 mm in the placebo group but no significant loss in the glucosamine group (P = 0.016). There were statistically significant improvements in both pain and physical function (P ≤ 0.05) in the glucosamine-treated patients using WOMAC scores. Symptoms worsened slightly in
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patients who received placebo. 43 Pavelka et al. 41 compared daily glucosamine sulphate and placebo over 3 years using an identical protocol. They studied 202 patients with knee OA randomized to receive either oral glucosamine sulphate 1500 mg/day or placebo. The primary endpoints were changes in radiographic minimum joint space width of the tibiofemoral joint and symptoms assessed by the Lequesne and WOMAC indices. The results showed a statistically significant difference in favour of glucosamine (P = 0.001). Average joint space narrowing after 3 years was 0.19 mm in the placebo group and 0.04 mm in the glucosamine group. In the placebo group, 14% of patients showed joint space narrowing of > 0.5 mm compared with 5% in the glucosamine group (P = 0.05). The symptoms improved modestly with placebo but by as much as 20 -25% with glucosamine. Differences in the Lequesne and WOMAC indices for pain, function and stiffness were statistically significant in favour of glucosamine (P < 0.05). 41 Bruyere et al., 35 in a similar study in 319
post-menopausal women with knee OA taking either 1500 mg/day of glucosamine sulphate or placebo, showed joint space loss of 0.33 mm with placebo and a small gain of 0.003 mm in patients receiving glucosamine. There was a 14.1% improvement in the WOMAC score with glucosamine and a deterioration of 5.4% with placebo. 39 Christgau et al. 53 showed that collagen II degradation, a measure of cartilage turnover, decreased over 12 months in 21 glucosamine group versus 52% in the ibuprofen group at the end of week 4 Lequesne Index decrease: > 6 points in both groups. 35% of patients on ibuprofen reported adverse events versus 6% on glucosamine 1500 mg/day glucosamine versus Pain reduction: 71% in the glucosamine group versus 1200 mg/day ibuprofen 19 61% in the ibuprofen group at the end of month 3 Glucosamine treatment was associated with a significantly greater decrease in pain and paracetamol use between days 90 and 120 (carry-over effect) 1500 mg/day glucosamine versus Pain reduction: 51% in the glucosamine group versus 1200 mg/day ibuprofen 20 57% in the ibuprofen group at the end of week 4 Knee swelling: 77% in the glucosamine group versus 78% in the ibuprofen group at the end of week 4 Symptom improvement: 84% in the glucosamine group versus 77% in the ibuprofen group at the end of week 4 Glucosamine was 18% safer than ibuprofen 1500 mg/day glucosamine versus Pain scores decreased faster during the first 2 weeks in 1200 mg/day ibuprofen 22 the ibuprofen than in the glucosamine treatment group The reduction in pain scores was significantly in favour of glucosamine at week 8 (P < 0.05)
patients on glucosamine and the changes correlated with changes in joint space, indicating that the best response to glucosamine was achieved in patients with the highest cartilage turnover or the most active disease. Finally, Altman et al. 54 looked at the need for arthritis-related surgery in two groups of patients followed up 5 years after the formal glucosamine sulphate and placebo comparison. Surgery was required in 14.7% of 177 patients studied. Twice as many patients originally treated with placebo required surgery, a 48% increase in risk compared with patients treated with glucosamine, an almost significant difference (P = 0.06). Time-to-event analysis confirmed a decreased cumulative reduction in risk among patients who had been on glucosamine (P = 0.05). 54 Because many of the glucosamine studies have been large scale and for long periods of time, it is not surprising that a meta-analysis provided little additional information. 18 Poolsup et al. 55 showed symptomatic relief and delayed progression of knee OA. The risk of disease progression was reduced by 54%, while glucosamine sulphate caused no more sideeffects than placebo. Richey et al. 50 similarly confirmed the chondroprotective action of both glucosamine and chondroitin in knee OA, as well as a pronounced effect on symptoms and no more adverse effects than placebo.
The long-term follow-up of the GAIT study was unable to show a statistically significant difference in joint space width between placebo and any of the active treatments (glucosamine, chondroitin or glucosamine plus chondroitin) after 2 years. 56 Knees with Kellgren-Lawrence grade 2 radiographic OA appeared to have the greatest potential for medication-related improvements associated with these treatments.
EFFICACY OF CHONDROITIN ALONE
Studies published to date also indicate that the use of chondroitin alone is effective in the management of OA (Table 9) , 49,57 -64 although the evidence is not as extensive as for glucosamine. The eight studies detailed in Table 9 are all well-controlled studies that meet the criteria of: (i) being published in peer-reviewed journals; (ii) having ethics committee approval; (iii) providing information on study design, patient characterization, inclusion/exclusion criteria, and treatment allocation; (iv) providing information on study endpoint(s), methodologies for efficacy and safety assessments, and statistical methodology; and (v) presenting results for both efficacy and safety. As with glucosamine, no studies of chondroitin alone have shown any significant safety concerns.
IMPACT OF CHONDROITIN ON THE COURSE OF OA
Verbruggen et al. 65 64 reported a multicentre study with 110
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patients. The Lequesne Index improved by 36% in the chondroitin group and by 22% in the placebo group (P ≤ 0.01). Michel et al. 67 compared chondroitin sulphate 800 mg/day and placebo in 300 patients with knee OA treated for 2 years. There was no change in joint space in chondroitin-treated patients but there was a significant reduction in those receiving placebo (mean joint space width P = 0.001; minimum joint space width P = 0.05). Between-group comparison showed a statistically significant difference in both the mean (P = 0.04) and minimum (P = 0.05) joint space width in favour of chondroitin. 67 There is no doubt that effect sizes are small with both glucosamine, chondroitin, or their combination in the treatment of OA. Nevertheless, nutraceutical products are very popular with patients and, generally, patients will not continue to pay for therapies that they perceive to be ineffective. The consensus of the clinical evidence is that glucosamine and/or chondroitin are most effective in OA of the knee and that both are slow acting. Both symptomatic and structure-modifying effects have been documented. The OARSI recommendations for glucosamine and/or chondroitin are as follows: 'Treatment with glucosamine and/or chondroitin sulphate may provide symptomatic benefit in patients with knee OA'; and 'In patients with symptomatic knee OA glucosamine sulphate and chondroitin sulphate may have structure-modifying effects.' 10 
SAFETY PROFILE OF GLUCOSAMINE AND CHONDROITIN
No serious adverse events have been reported with glucosamine or chondroitin and treatment-related deaths do not appear in the literature. The incidence of adverse events is comparable with that of placebo.
There is no evidence of any clinically significant interaction with glucosamine or chondroitin. 18 There has been concern about the use of glucosamine in patients with diabetes, but Tannis et al. 68 showed no changes in glucose levels or serum insulin concentrations in healthy individuals. Scroggie et al. 69 studied type 2 diabetes patients over a 90-day period during which they received either placebo or 1500 mg/day glucosamine hydrochloride and 1200 mg/day chondroitin sulphate. There were no significant changes in haemoglobin A 1C . Caution should be exercised in patients with extensive allergies, particularly those who are allergic to shellfish since glucosamine is made from crab shells. One case of angio-oedema has been reported, as well as photosensitivity. 70 Exacerbation of asthma has also been recorded. 71 The most common side-effects reported in studies with glucosamine and chondroitin are mild gastrointestinal (GI) symptoms, including abdominal pain, diarrhoea, heartburn, nausea, epigastric pain and flatulence. 46 These occurred in 3.5% of 1208 patients reported by Tapadinhas et al. 46 treated with glucosamine sulphate 1500 mg/day. Amongst the non-GI adverse events are drowsiness and skin reactions, which are of doubtful significance. 46 
GLUCOSAMINE AND CHONDROITIN -SUMMARY AND CONCLUSIONS
There is good evidence that glucosamine, chondroitin and their combination can provide symptomatic benefit in OA, especially in OA of the knee, and expert opinion is that they may also have a structure-modifying effect. Thus, the use of these nutraceutical agents is recommended by the EULAR and OARSI expert guidelines. 9, 10 In the author's opinion, glucosamine is probably slightly more
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effective than chondroitin and their combination is more effective than either agent used alone. These nutraceuticals are not effective in every case of OA but, since they are slow acting agents, they should be continued at the recommended daily doses for at least 1 month before discontinuing for lack of efficacy.
Topical therapy in mild-tomoderate OA joint pain management
Misconceptions abound in the treatment of OA. One of them is the widely held view that topical NSAIDs are just placebos or that they are not able effectively to penetrate the skin to reach the deep tissues affected by OA. The act of rubbing is, of course, the oldest way of relieving pain and amongst the best. The application of a placebo gel has been demonstrated to have an effect, but the evidence clearly shows that antiinflammatory gels are more effective than placebo in OA and in other conditions like soft tissue injuries or rheumatism. 72 In fact, the evidence suggests that topical NSAIDs are as effective as systemically-administered NSAIDs and have a good safety profile, suggesting that they are the best candidates for the first-line pharmacological treatment of mild-to-moderate joint pain due to OA. 9, 73 
PHARMACOKINETICS
Scepticism still exists about the ability of topically-applied NSAIDs to penetrate the skin to reach the joint. This scepticism has prompted intensive investigation of the pharmacokinetics of topical NSAIDs and a large body of evidence confirms that NSAIDs rapidly penetrate the skin and to a significant depth to exert an effective antiinflammatory activity following topical administration. 74 The kinetics of topicallyapplied diclofenac have been the most thoroughly investigated and provide convincing evidence of the ability of topical NSAIDs to reach the joint compartment. For example, the evidence demonstrates that diclofenac provided in the form of a gel penetrates the skin, 75 -78 that the skin provides a reservoir for supplying active drug to deeper tissues, 79, 80 and that diclofenac is concentrated in the synovium 77,78,81 -83 and replenished from the systemic circulation, but that systemic absorption is much lower than that achieved with oral administration. 77 The excellent skin penetration of topically-applied diclofenac seems to be partly a result of the comparatively small size and molecular structure of the diclofenac molecule itself, since significant penetration is obtained after application of a simple aqueous solution. 77, 84 Penetration can be enhanced by the formulation and, whilst most experience has been with the gel base, enhanced percutaneous absorption compared with an aqueous solution has been demonstrated with a diclofenac lotion when used in a multidose regimen but not after a single dose. 85 There was continuous delivery of diclofenac from the lotion into and through the skin, which ceased when the dosing site was washed. 86 Another study utilizing a diclofenac spray gel demonstrated higher levels of diclofenac in skeletal muscle and adipose tissue after topical use compared with oral administration. 87 By contrast, maximum diclofenac levels in plasma were approximately 250-fold lower after topical compared with oral administration. 87 Most recently, in a comparison of 7 days of treatment with oral diclofenac (50 mg three times daily) and topical diclofenac 16 g/day in four divided doses applied to one knee, systemic exposure to diclofenac was 
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more than 15-fold higher in the oral-dosed group. 88 When the same oral dose of diclofenac was compared with the 16 g/day gel applied to each knee, together with 8 g/day gel applied to each hand in the same four-times-daily regimen (total dose 48 g/day), the systemic exposure was still fivetimes greater following oral dosing compared with topical application. 88 In animal and human studies, topical diclofenac has been shown to penetrate deep through the skin to a depth up to 1 cm, 76, 89 while significant concentrations of the drug have been detected in deeper tissues such as the joint. 82 Only 3 -7% of the applied dose of diclofenac is systemically absorbed compared with a bioavailability of over 90% for oral administration. 78, 83 Peak plasma concentrations of diclofenac after repeat topical administration of diclofenac gel are about 50-times less than with oral administration and 100-times less after a single topical administration. 78 Peak plasma concentrations are achieved 1 -2 h after topical administration. 80 Peak concentrations in skin are achieved 2 h after application, with a second peak 10 h after application which is attributed to the systemic circulation. The skin seems to act as a 'reservoir' from which the drug is distributed to deeper tissues. 79, 80 Direct distribution of the drug through superficial to deeper tissues has been observed in humans. 89 The diclofenac concentration versus time profile was similar for both types of tissues (area under the curve of 532 ± 197 µg/min per ml for superficial layers and 438 ± 249 µg/min per ml for deep layers). 89 Concentrations of diclofenac in synovial fluid and joint tissue are up to 20-times higher than in plasma, showing that diclofenac is concentrated there. 78 
EFFICACY
There is a large body of clinical evidence demonstrating the clinical efficacy of topical NSAIDs in the management of mild-tomoderate pain due to OA. 72 Furthermore, treatment with topical NSAIDs can help to improve the functional capacity of patients, resulting in improved mobility. 72 Topical NSAID therapy is recommended as the firstline therapy before the use of systemic NSAIDs by all of the expert guidelines and evidence suggests that it is at least as effective as systemic NSAID therapy (Table  10) . 10, 12 Topically-applied diclofenac has been the most assessed in the treatment of OA pain, against both placebo and oral analgesics, followed by topical ibuprofen. In 2008, Banning 90 reviewed the RCTs that had assessed the efficacy of topical diclofenac as a method of pain relief in OA of the knee,
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concluding that topical diclofenac is either superior or equivalent to oral diclofenac and that it significantly reduced pain and morning stiffness and improved physical function and patient global assessment without major adverse effects in patients with OA of the knee. Altman and Barkin 73 came to a similar conclusion, suggesting that topical diclofenac 'has produced statistically significant and clinically meaningful improvements in pain discomfort and function in osteoarthritic hands and knees with no adverse effects attributed to treatment'. Finally, Zacher et al. 77 also concluded in their systematic review that topical diclofenac is effective in a range of body pain conditions, including hand and knee OA, demonstrating a significant superiority to placebo and at least a parity to oral NSAIDs, such as ibuprofen 1200 mg/day, whilst having a positive impact on stiffness and physical function in patients with OA of the knee. In contrast to topical diclofenac, Altman and Barkin 73 found that other agents sometimes used topically in OA, i.e. capsaicin and salicylates, lacked evidence of skin penetration and/or significant efficacy compared with placebo. 
SAFETY PROFILE OF TOPICAL NSAIDs
An advantage of topical NSAIDs is that, unlike their systemic formulations, GI sideeffects are less likely. Indeed, case-control studies have not shown any association between topical NSAID use and serious GI events, renal toxicity or cardiovascular risk. 73 The most common adverse events experienced are usually mild local skin reactions that quickly resolve. 72 Phototoxic or photoallergic reactions may occur but are rare with topical diclofenac and are most often seen with topical ketoprofen. 77 Indeed, the unfavourable risk-to-benefit profile of topical ketoprofen, due to the risk of rare but serious photoallergic reactions, set against its weak-to-moderate efficacy, resulted in suspension by the French Health Authorities (AFSSAPS) of all of the topical ketoprofen products available in France. 109 Among the topical NSAIDs, topical diclofenac preparations have a long record of safety since they have been used for many years by millions of patients, being the most widely used topical NSAID for body pain conditions. Overall, the available data indicate that the safety profile of topical diclofenac is remarkably good with an incidence of adverse effects of only 1.4% in > 13 000 people treated with the Voltaren ® Emulgel ® formulation alone. 77, 110 Up to 96% of patients treated rated the acceptability of this formulation as 'fair' to 'excellent'. 77, 79 The only caution is for patients with allergies, including asthma. Patients with hypersensitivity reactions like angioneurotic oedema should not be given antiinflammatory drugs in any form. The British Committee on the Safety of Medicines has issued a warning that any degree of worsening asthma may be related to the use of NSAIDs. 111 Physicians may be tempted to add topical to oral NSAID therapy in the expectation of improved efficacy in controlling exacerbations of pain, but may also be concerned about the potential for an EC Huskisson A holistic approach to pain management in osteoarthritis Compared with placebo, diclofenac showed:
• Greater improvement in diary-based assessments of: • The same rate of adverse events (9% -Day pain on movement over 1 -14 days patients with ≥ 1 adverse event)
(difference 4 mm, P = 0.02), especially on days • Superior end of study OARSI-OMERACT response rate (62% versus 46%, respectively, P = 0.01)
• Greater patient-rated efficacy, with more patients rating 'good' to 'excellent' (69% versus 58%, respectively, P = 0.03)
• Efficacy was greater with longer washout (> 4 days) Compared with placebo, diclofenac showed:
• Greater change in pain (mean -5. • No difference in withdrawals due to adverse events (9/107 versus 9/109, respectively) 93 Compared with vehicle and placebo, diclofenac showed: Compared with vehicle and placebo,
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• Greater reduction in pain (-3.9 versus -2.5 and -2.5, diclofenac showed: P = 0.023 and P = 0.016, respectively)
• Greater incidence of minor skin
• Greater reduction in physical function (-11.6, dryness/flakiness at application site (36% P = 0.002 and P = 0.014, respectively), stiffness versus 14% and 1%, respectively) (-1.5, P = 0.015 and P = 0.002, respectively) and
• No difference in GI events or other pain on walking (-0.8, P = 0.003 and P = 0.015, reactions (no contact dermatitis) respectively)
• No significant difference in withdrawals
• Better PGA score (P = 0.039 and P = 0.025, due to adverse events (6% versus 4% respectively) and 0%, respectively)
• Lower paracetamol consumption (36.2 tablets versus 49.5 and 54.9, respectively)
• Lower patient dropout rate due to lack of effect (2% versus 10% and 12%, P = 0.05 and P = 0.02, respectively)
Knee OA Roth et al., 2004 94 Compared with vehicle, diclofenac showed:
Compared with vehicle, diclofenac showed:
• Greater reduction in WOMAC pain (-5. respectively; two rash, one pruritus, one
• Greater patient-and investigator-rated efficacy nausea), none of which was severe and ('excellent': 24.5% versus 8.9% and 10.2% versus all resolved spontaneously; two events in 8.9% patients, respectively, P < 0.05 and P < 0.01) the placebo group led to a break in treatment EC Huskisson A holistic approach to pain management in osteoarthritis Compared with placebo, diclofenac showed:
Tisne-Camus, 1993 99 • Greater reduction in pain from day 4 (P < 0.001),
• • Lower analgesic (paracetamol) consumption from day 7 (1.00 versus 2.90, respectively, P < 0.01) to day 15 (2.53 versus 8.83, respectively, P < 0.005)
• Greater physician-and patient-rated global efficacy ('good' or 'excellent': 64% versus 23% and 71% versus 27%, respectively, P < 0.0001)
• Fewer patients discontinuing treatment (one versus 12, respectively, P < 0.0001) 'very good' in at least 90% of cases 10.45 ± 2.02 versus 7.67 ± 2.41)
• Overall assessment (patient: 60% good or very good for ibuprofen and 28% for placebo; investigator: 74% and 28%, respectively) A holistic approach to pain management in osteoarthritis • Pain while resting also improved in both groups • Average value of pain scores for the intensity of night-time pain were reduced significantly from 13.5 to 3.0 (P < 0.01) for piroxicam patients, and from 13.0 to 4.0 (P < 0.01) for diclofenac patients
• For the parameters walking and climbing stairs, similar significant improvements were recorded in both groups
• In 80% of the patients, the treating physician assessed the efficacy of piroxicam gel as good/ excellent versus 74% in the diclofenac group EC Huskisson A holistic approach to pain management in osteoarthritis • At day 14, significant differences were observed for tenderness (37% versus 15%, respectively, P < 0.001) and restriction of active movement (31% versus 16%, respectively, P < 0.016)
• At day 28, the reduction in symptoms ranged between 20 -24% for the systemic group and between 32 -41% for the piroxicam group
• Scores for tenderness were significantly in favour of the piroxicam group (P < 0.025)
• Scores for pain at rest and during active movement as well as stiffness were lower for the piroxicam group, but the difference was not significant
• An assessment of quality of life (rated by both patients and investigators) also favoured treatment with the gel (day 28: excellent or good for 62% in the systemic group versus 72% in the piroxicam group)
• The reduction of mean scores in the AIMS scale (for pain, physical and psychological function) were significantly better for the piroxicam group EC Huskisson A holistic approach to pain management in osteoarthritis increase in adverse effects. These expectations and associated concerns have recently been explored in a large-scale, multiarm controlled study in which oral and topical diclofenac and their combination were compared with placebo and the topical lotion vehicle in the treatment of pain and functional improvement in knee OA, as measured by the WOMAC index score over a period of 12 weeks. 112 Topical and oral diclofenac were found to be almost equally effective in the management of pain and physical function, and their combination produced a further, but non-statistically significant, improvement in both parameters. Reassuringly, the authors found that the addition of topical to oral diclofenac did not increase the incidence of systemic side-effects.
Oral medications for mildto-moderate OA joint pain SIMPLE ANALGESICS
All of the guidelines recommend beginning drug therapy with the oral analgesic paracetamol (acetaminophen). 9 -11 This is effective in OA pain and, at recommended doses, it has an excellent safety record even in long-term use. 10 Unfortunately, most patients presenting in the clinic will already have been using paracetamol and found it to be insufficiently effective. Combinations of analgesics are more effective than paracetamol alone: such as paracetamol with dextropropoxyphene or, if pain is severe, paracetamol in combination with tramadol. Most patients will need a simple analgesic if only occasionally and it is a good idea to find the one that suits them. Occasionally opiates are needed, for example with advanced disease that is not amenable to surgery. Physicians are reluctant to prescribe potentially addictive drugs, although experience suggests that A holistic approach to pain management in osteoarthritis addiction is not a problem in this sort of indication. Oral morphine-like drugs or patches can be used in these circumstances.
ORAL NSAIDs
For many years, oral NSAIDs have been the mainstay of symptomatic treatment of mildto-moderate OA and meta-analysis shows that they may be effective in the short-term in many patients. 113 The poor GI tolerability of these agents and the potential for serious adverse effects has, however, led the expert groups to recommend first the use of paracetamol at doses of up to 4 g/day, resorting to alternative or adjunctive NSAID treatment if (as is often the case) paracetamol proves insufficiently effective. 10, 12 The development of cyclo-oxygenase (COX)-selective NSAIDs has, as expected, reduced the incidence of GI adverse effects, but the potential for cardiovascular events has been shown to be increased with COX-2 inhibitors, 12 creating a dilemma for the prescriber. Where oral NSAIDs must be used in chronic treatment, the selection of agents with a better side-effect profile or coprescription of misoprostol or a proton pump inhibitor can reduce, but not eliminate, the GI risk. 12 Expert opinion recommends that oral NSAIDs should be used at the lowest possible effective doses and for the shortest duration of time in the management of OA. 114 With the availability of effective topical treatment for OA pain, the need for oral NSAIDs has undoubtedly diminished. 9 -12 Since the symptoms of OA are cyclic, 'background' treatment with a topical NSAID for recurrent mild-to-moderate pain, coupled with intermittent dosing with an oral NSAID (at the lowest effective dose for a short period of time) to treat acute, inflammatory pain exacerbations could prove to be effective, while reducing the hazards of long-term use.
Undoubtedly, NSAIDs are very effective in OA. Many studies have shown that they are more effective than simple analgesics. They do more than just relieve pain, for example reducing stiffness. Patients usually prefer them to simple analgesics but they do have disadvantages, particularly for an elderly OA population which may have other diseases and may be taking other drugs. The risks of oral NSAIDs increase with both increasing doses and length of treatment 10 and the relative safety of short-term, lowdose treatment has been recognized by the registration authorities with the licensing of low-dose OTC NSAIDs, such as diclofenac or ibuprofen tablets limited to a short duration of treatment. For example, low-dose, diclofenac-K, immediate release, sugarcoated tablets have gained approval by various health authorities worldwide for OTC use to treat acute pain in a maximum single dose of 25 mg and a maximum daily dose of 75 mg. Diclofenac-K is rapidly absorbed from the stomach, reaching maximum plasma levels in < 30 min, 115 and its efficacy has been confirmed in numerous pain syndromes, including aches and pains in muscles, joints and the back. 116, 117 Lowdose oral NSAIDs, such as diclofenac could, therefore, be a useful addition to the range of treatments available for OA and could be particularly suited to short-term joint pain exacerbations, which are a feature of the disease.
The incidence of adverse events with lowdose diclofenac-K is similar to that of lowdose ibuprofen and placebo. 115 Patients with renal disease or a history of allergic reactions or asthma aggravated by NSAIDs should not be given even low-dose NSAIDs. The overall safety of low-dose diclofenac is considered good and a community-based study in Norway, intended to be as close to real life as EC Huskisson A holistic approach to pain management in osteoarthritis possible, demonstrated that there were no serious adverse events that were considered to be treatment related. 117 A total of 36 adverse events occurred in 25 patients and the most common were abdominal pain or discomfort, headache and nausea. Only six participants (1.6%) had an adverse event thought to be probably related to treatment.
A particular regime for a particular patient
The secret to successful pain management in OA is to match the treatment to the patient. Table 12 shows a selection of patients and their clinical problems to illustrate the variations that occur in OA and how these should influence treatment choice.
Conclusion
Managing the mild-to-moderate symptoms of OA is more complicated than just prescribing a tablet or giving an injection and a firm diagnosis is an essential prelude to successful treatment, followed by assessment. For example, the treatment for a 50-year old lady with a single painful thumb is not going to be the same as for that of an 80-year old with painful swollen knees and ankles. Patient education and advice are the cornerstones of the successful management of this chronic condition. There are new ideas in OA management and new options for the patient with mild-to-moderate symptoms. Among the most important of these management options are: (i) the importance of non-drug measures such as diet, exercise and patient information; (ii) the value of nutraceuticals such as glucosamine and chondroitin; (iii) the possibility of achieving the same efficacy with a topical NSAID as with an oral formulation; and (iv) the opportunities that oral low-dose NSAIDs or simple analgesics could provide as first-line or add-on therapy to topical NSAID treatment. The most important factor is to match the needs of the patient with the increasing array of treatment possibilities. With safety in mind, we must remember to use less harmful treatment modalities such as nutraceutical supplements, exercises and topical NSAIDs; when we must use oral drugs, we should go for the lowest effective doses and the shortest effective periods of treatment.
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